Evidence map›Paper›PMID 11982591›Full record

ArticleClinical and experimental immunology2002

Activated macrophages for treating skin ulceration: gene expression in human monocytes after hypo-osmotic shock.

O Frenkel, E Shani, I Ben-Bassat, F Brok-Simoni, G Rozenfeld-Granot, G Kajakaro, G Rechavi, N Amariglio, E Shinar, D Danon

Registry-linked trialOpen access · bronzeAbstract readComparative Study
In one paragraph

Article in Clinical and experimental immunology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01038986 (A Post-marketing Multi-center Observational Study to Provide Data Describing the Safety and Effectiveness of CUREXCELL™ as it is Applied in a Real-life Setting for Treatment in Patients With Chronic and/or Refractory Wounds), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01038986 completednot on this mapstarted 2009, after this paper: background citation

A Post-marketing Multi-center Observational Study to Provide Data Describing the Safety and Effectiveness of CUREXCELL™ as it is Applied in a Real-life Setting for Treatment in Patients With Chronic and/or Refractory Wounds

TypeobservationalSponsorMacrocure Ltd.Ran2009 to 2012Enrolled70ConditionsWoundsArmsCureXcell
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Macrophages as a therapeutic target to promote diabetic wound healing.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Anti-inflammatory macrophages improve skeletal muscle recovery from ischemia-reperfusion.Journal of applied physiology (Bethesda, Md. : 1985) · 2015
    Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

O FrenkelDepartment of Haematology, Chaim Sheba Medical Centre, Tel-Hashomer, Israel.
E Shani
I Ben-Bassat
F Brok-Simoni
G Rozenfeld-Granot
G Kajakaro
G Rechavi
N Amariglio
E Shinar
D Danon
Sheba Medical Center · ILTel Aviv University · ILMagen David Adom · ILWeizmann Institute of Science · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophages play a major role in almost all stages of the complex process of wound healing. It has been previously shown that the incorporation of a hypo-osmotic shock step, in the process of monocyte-concentrate preparation from a blood unit, induces monocyte/macrophage activation. As the macrophages are produced using a unique, closed and sterile system, they are suitable for local application on ulcers in elderly and paraplegic patients. Enhanced phagocytosis by the activated cells, as well as increased secretion of cytokines such as IL-1, IL-6, were detected in a recent study which are in accord with the very encouraging clinical results. In the present study, we used DNA microarrays to analyse the differential gene expressions of the hypo-osmotic shock-activated monocytes/macrophages and compare them to non-treated cells. Of the genes that exhibited differences of expression in the activated cell population, 94% (68/72) displayed increased activity. The mRNA levels of 43/68 of these genes (63%) were found to be 1.5-fold or higher (1.5-7.98) in the activated macrophages cell population as compared to the non-treated cells. Only four genes were found to have lower mRNA levels in the activated cells, with ratios of expression of 0.62-0.8, which may suggest that the changes are insignificant. A significant number of the genes that showed increased levels of expression is known to be directly involved in macrophage function and wound healing. This may correlate with the increased secretion of different cytokines by the activated macrophages depicted previously. Other groups of genes expressed are known to be involved in important pathways such as neuronal growth and function, developmental defects and cancer. The hypo-osmotic shock induces a gene expression profile of cytokines and receptors in the activated cells. These may evoke potential abilities to produce a variety of protein products needed in the wound healing process and may bring to light possibilities for other therapeutic applications of these cells.

Indexed as

Macrophage ActivationCell Culture TechniquesCells, CulturedCytokinesGene Expression ProfilingGene Expression RegulationGrowth SubstancesHumansMacrophagesMonocytesOligonucleotide Array Sequence AnalysisOsmotic PressureReceptors, ImmunologicRNA, MessengerSkin UlcerCytokinesGrowth SubstancesReceptors, ImmunologicRNA, Messenger

Identifiers

PMID11982591
PMCPMC1906371
OpenAlexW2074031701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.